Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TEM Stock Forecast 2026-2027
$49.86
Current Price
$8.95B
Market Cap
Buy 10
Hold 6
Sell 1
Wall St Analyst Ratings
Distance to TEM Price Targets
+100.6%
To High Target of $100.00
+36.4%
To Median Target of $68.00
-29.8%
To Low Target of $35.00
TEM Price Momentum
-9.3%
1 Week Change
+12.9%
1 Month Change
-18.8%
1 Year Change
-15.6%
Year-to-Date Change
-52.2%
From 52W High of $104.32
+19.5%
From 52W Low of $41.73
📊 TOP ANALYST CALLS
Did TEM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tempus AI is one of their latest high-conviction picks.
Latest TEM Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, TEM has a bullish consensus with a median price target of $68.00 (ranging from $35.00 to $100.00). The overall analyst rating is Buy (7.9/10). Currently trading at $49.86, the median forecast implies a 36.4% upside. This outlook is supported by 10 Buy, 6 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Bradley Bowers at Mizuho, projecting a 100.6% upside. Conversely, the most conservative target is provided by Tycho Peterson at Jefferies, suggesting a 29.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TEM Analyst Ratings
10
Buy
6
Hold
1
Sell
TEM Price Target Range
Low
$35.00
Average
$68.00
High
$100.00
Current: $49.86
Latest TEM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TEM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2026 | TD Cowen | Dan Brennan | Buy | Maintains | $68.00 |
| Apr 13, 2026 | Jefferies | Tycho Peterson | Underperform | Initiates | $35.00 |
| Mar 30, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $60.00 |
| Mar 11, 2026 | Needham | Ryan MacDonald | Buy | Reiterates | $75.00 |
| Mar 9, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $95.00 |
| Mar 3, 2026 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $70.00 |
| Feb 25, 2026 | JP Morgan | Casey Woodring | Neutral | Maintains | $60.00 |
| Feb 25, 2026 | Needham | Ryan MacDonald | Buy | Maintains | $75.00 |
| Feb 25, 2026 | BTIG | Mark Massaro | Buy | Maintains | $90.00 |
| Feb 19, 2026 | Mizuho | Bradley Bowers | Outperform | Initiates | $100.00 |
| Feb 17, 2026 | Baird | Catherine Schulte | Outperform | Initiates | $59.00 |
| Dec 22, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $80.00 |
| Dec 15, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $80.00 |
| Dec 2, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $85.00 |
| Nov 25, 2025 | BTIG | Mark Massaro | Buy | Maintains | $105.00 |
| Nov 11, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $80.00 |
| Nov 11, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $80.00 |
| Nov 7, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $89.00 |
| Nov 5, 2025 | Needham | Ryan MacDonald | Buy | Maintains | $100.00 |
| Nov 5, 2025 | BTIG | Mark Massaro | Buy | Reiterates | $96.00 |
Tempus AI, Inc. (TEM) Competitors
The following stocks are similar to Tempus AI based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tempus AI, Inc. (TEM) Financial Data
Tempus AI, Inc. has a market capitalization of $8.95B with a P/E ratio of 39.3x. The company generates $1.36B in trailing twelve-month revenue with a -22.2% profit margin.
Revenue growth is +36.1% quarter-over-quarter, while maintaining an operating margin of -24.3% and return on equity of -81.6%.
Valuation Metrics
Market Cap
$8.95B
Enterprise Value
$10.29B
P/E Ratio
39.3x
PEG Ratio
-551.0x
Price/Sales
6.6x
Growth & Margins
Revenue Growth (YoY)
+36.1%
Gross Margin
+64.7%
Operating Margin
-24.3%
Net Margin
-22.2%
EPS Growth
+83.0%
Financial Health
Cash/Price Ratio
+7.1%
Current Ratio
3.3x
Debt/Equity
316.6x
ROE
-81.6%
ROA
-9.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tempus AI, Inc. (TEM) Business Model
About Tempus AI, Inc.
What They Do
Healthcare technology company focused on AI-driven diagnostics.
Business Model
Tempus AI, Inc. generates revenue by offering advanced diagnostic platforms and genomics services to healthcare providers, pharmaceutical and biotech companies. Their AI applications and software as a medical device enhance clinical decision-making and support drug development processes, creating value through personalized medicine and improved patient outcomes.
Additional Information
Founded in 2015 and based in Chicago, Illinois, Tempus AI, Inc. leverages extensive clinical and molecular data libraries alongside machine learning technologies to transform precision medicine. Their FDA-cleared tools and innovative solutions are positioned to significantly impact the healthcare landscape by addressing care gaps and facilitating targeted treatment options.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
3,800
CEO
Mr. Eric P. Lefkofsky J.D.
Country
United States
IPO Year
2024
Website
www.tempus.comTempus AI, Inc. (TEM) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Tempus AI (TEM) Reports Q1 Loss, Beats Revenue Estimates
Tempus (TEM) delivered earnings and revenue surprises of +38.10% and +0.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 05, 2026
By Zacks Equity Research
Tale of the Tape
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
Apr 30, 2026
By Sridatri Sarkar
Analyst Blog
Latest News
Quick Summary
Tempus AI, Inc. (TEM) held its Q1 2026 earnings call, where it discussed financial performance and strategic initiatives. Further details can be accessed in the full transcript.
Why It Matters
The Q1 2026 earnings call for Tempus AI, Inc. provides insights into the company's financial health, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Tempus AI shows long-term growth potential with strong Oncology testing and record $1.1B TCV. Q1 mixed results included narrowing losses and gross margin expansion despite decelerating revenue growth.
Why It Matters
Tempus AI's strong TCV and high net revenue retention signal robust demand, despite mixed Q1 results. Its expanding market beyond Oncology could drive future growth, making it a potential long-term investment.
Source: Seeking Alpha
Market Sentiment:
Positive
Tempus Reports First Quarter 2026 Results
4 days ago
Quick Summary
Tempus AI, Inc. (NASDAQ: TEM) reported Q1 2026 revenue of $348.1M, a 36.1% increase year-over-year. Diagnostics revenue rose to $261.1M, up 34.7%, boosted by a 28% increase in Oncology tests.
Why It Matters
Tempus AI's strong revenue growth and significant increase in diagnostics volume indicate robust demand and market potential, which can enhance investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Tempus AI reported a quarterly loss of $0.13 per share, beating the Zacks Consensus Estimate of $0.21. This is an improvement from a loss of $0.24 per share a year earlier.
Why It Matters
Tempus AI's smaller-than-expected quarterly loss indicates improving financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Tempus AI reported a narrower Q1 loss and 36% revenue growth, but shares fell after hours due to concerns over operating losses and rising costs.
Why It Matters
Tempus AI's revenue growth indicates strong demand, but rising costs and operating losses raise concerns about profitability, affecting investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Tempus AI, Inc. plans to offer $350 million in Convertible Senior Notes due in 2032 through a private placement, pending market conditions, targeting qualified institutional buyers.
Why It Matters
Tempus AI's $350 million convertible notes offering indicates a significant capital raise, potentially enhancing its growth and innovation in AI and precision medicine, impacting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About TEM Stock
What is Tempus AI, Inc.'s (TEM) stock forecast for 2026?
Based on our analysis of 18 Wall Street analysts, Tempus AI, Inc. (TEM) has a median price target of $68.00. The highest price target is $100.00 and the lowest is $35.00.
Is TEM stock a good investment in 2026?
According to current analyst ratings, TEM has 10 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $49.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TEM stock?
Wall Street analysts predict TEM stock could reach $68.00 in the next 12 months. This represents a 36.4% increase from the current price of $49.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tempus AI, Inc.'s business model?
Tempus AI, Inc. generates revenue by offering advanced diagnostic platforms and genomics services to healthcare providers, pharmaceutical and biotech companies. Their AI applications and software as a medical device enhance clinical decision-making and support drug development processes, creating value through personalized medicine and improved patient outcomes.
What is the highest forecasted price for TEM Tempus AI, Inc.?
The highest price target for TEM is $100.00 from Bradley Bowers at Mizuho, which represents a 100.6% increase from the current price of $49.86.
What is the lowest forecasted price for TEM Tempus AI, Inc.?
The lowest price target for TEM is $35.00 from Tycho Peterson at Jefferies, which represents a -29.8% decrease from the current price of $49.86.
What is the overall TEM consensus from analysts for Tempus AI, Inc.?
The overall analyst consensus for TEM is bullish. Out of 18 Wall Street analysts, 10 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $68.00.
How accurate are TEM stock price projections?
Stock price projections, including those for Tempus AI, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 2:38 PM UTC